

20th Scandinavian Meeting on Parkinson´s Disease and Related Disorders

Program committee and organisation

Aasly, Jan, Norway	jan.aasly@ntnu.no
Bjornsdottir, Anna, Iceland	abjorns@gmail.com
Dietrichs, Espen, Norway	espen.dietrichs@klinmed.uio.no
Henriksen, Tove	Tove.Henriksen@regionh.dk
Hvid-Danielsen, Erik, Denmark	ehdanielsen@dadlnet.dk
Mardosiene, Skirmante	Skirmante.Mardosiene@regionh.dk
Martikainen, Mika, Finland	mika.martikainen@tyks.fi
Odin, Per, Germany	per.odin@klinikum-bremerhaven.de
Sven Pålhagen, Sweden	sven.palhagen@gmail.com
Sigurdadottir, Gudrun, Island	gudrun@setrid.is
Widner, Håkan, Sweden	hakan.widner@med.lu.se
Wiksten, Markus, Finland	markus.wiksten@hus.fi

Scientific Sponsor: Scandinavian Movement Disorder Society

Commercial Sponsors: AbbVie, Abbott, Zambon Sweden, Medtronic, Boston Scientific, Nordic Infucare, Lobsor

Organisation: Tiziana Saraceno [tiziana.saraceno@themeetingcompany.se]

Timepoint: 22-23 April 2022

Venue: Scandic Hotel, Holmenkollen

Language

The official languages of the symposium will be English and Scandinavian

Meeting Time Schedule

Friday	11.30 Lunch
	12.30-19.00 Lectures
	20.00 Dinner
Saturday	08.00-13.00 Lectures

Lectures

Each lecture should be 20 minutes long.

Scientific Program

Friday 22. April

11.30-12.25 Lunch and registration

12.25-12.30 Opening of the meeting

12.30-14.00 Pathogenesis

Where does PD start?

Per Borghammer, Denmark

Neurogenetics of PD: Update and clinical relevance

Thomas Gasser, Germany

Translational approaches to treatment of Parkinson´s disease

Mathias Toft, Norway

Symptomatology

14.00-14.30 Motor

Axial disturbances: Camptocormia, Pisa Syndrome, Antecollis, Retrocollis
Gunther Deuschl, Germany

14.30-15.00 Coffee

15.00-16.00 Non-motor

Comparing and contrasting the motor and non-motor effects of advanced therapies in PD

Ray Chaudhuri, England

Understanding depression in PD

Murat Emre, Turkey

16.00-17.00 Diagnostics

Biomarker-based early diagnosis of PD

Miles Trupp, Sweden

17.00-17.15 Coffee

17.15-17.45 Monitoring and Therapy of advanced PD

Placebo effects in PD

Joaquim Ferreira, Portugal

DBS: Latest developments

Elena Moro, France

17.45-18.45 Best papers

Best 3 experimental papers 2019-20

Anders Björklund, Sweden

Best 3 clinical papers 2019-20

Andrew Lees, England

18.45-19.15 Pro-Cons Session

Shall we start PD therapy with L-dopa?

Yes: Espen Dietrichs

No: Christian Oehlwein

Saturday 23. April

08.00-10.00 Monitoring and Therapy of advanced PD

Wearables for monitoring PD and its treatments

Filip Bergqvist, Sweden

Pump-based therapies for PD: state of the art

Tove Henriksen, Denmark

Differential Indication for Advanced therapies

Werner Poewe, Austria

Cognitive decline in PD: Clinical phenotype, imaging and treatment strategies

Irene Rektorova, Czech Republic

10.00-10.30 Coffee

10.30-11.00 Future treatment

Trophic factor-based therapy: Where are we standing?

Alan Whone, England

11.00-13.00 Non-PD Movement Disorders

MSA: Clinical manifestations and therapeutic options

Gregor Wenning, Austria

PSP: Clinical manifestations and therapeutic options

Gunther Höglinger, Germany

Therapeutic options for Dystonia

Marie Vidailhet, France

Tics and Tourette: Symptomatology and Clinical Management

Kirsten Muller-Vahl, Germany